LYPD1 promotes the progression of lung adenocarcinoma through activating the PI3K/AKT signaling pathway
Archives of Biochemistry and Biophysics · 2026-09 · 783 · 110906
DOI: 10.1016/j.abb.2026.110906 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Biochemistry and Biophysics, 2026-09. Verfasst von Hanxi Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, China. Electr…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Adenocarcinoma of Lung, Phosphatidylinositol 3-Kinases, Signal Transduction. Die Arbeit nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Lung adenocarcinoma (LUAD) is one of the most common cancers worldwide. LY6/PLAUR Domain Containing 1 (LYPD1) has been reported to be a potential predictive biomarker in various cancers, but its role in LUAD remains unclear. This study aimed to investigate the role of LYPD1 and its molecular mechanisms in LUAD. METHODS This study used a suite of bioinformatics tools to analyze the correlations between LYPD1 with clinical parameters, tumor microenvironment (TME) features, and drug sensitivity. The effects of LYPD1 on LUAD cells were detected by cell viability, cell migration, flow cytometry and Western blot assays. Furthermore, the role of LYPD1 in LUAD was verified in a xenograft model. RESULTS The expression of LYPD1 was upregulated in LUAD tissues and associated with the TME parameters. In vitro experiments revealed that LYPD1 promoted the proliferation and migration of LUAD cells. Molecular mechanism results showed that the PI3K/AKT signaling pathway was further activated after LYPD1 overexpression. In vivo, the study confirmed that LYPD1 promoted the development of LUAD tumors in mice. CONCLUSIONS This study suggests that LYPD1 plays a tumor-promoting role in LUAD and may serve as a predictive biomarker and a potential therapeutic target for LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, China. Electronic address: zhouhq2156@enzemed.com.
- Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, China. Electronic address: guoyq5674@enzemed.com.
- Department of Pathology, Taizhou Hospital, Wenzhou Medical University, Linhai, 317000, China. Electronic address: zhoup@enzemed.com.
- Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, 317000, China. Electronic address: zhengjingmin@enzemed.com.
Zitieren
APA
Zhou, H., Guo, Y., Zhou, P., & Zheng, J. (2026). LYPD1 promotes the progression of lung adenocarcinoma through activating the PI3K/AKT signaling pathway. Archives of Biochemistry and Biophysics, 783, 110906. https://doi.org/10.1016/j.abb.2026.110906
Vancouver
Zhou H, Guo Y, Zhou P, Zheng J. LYPD1 promotes the progression of lung adenocarcinoma through activating the PI3K/AKT signaling pathway. Archives of Biochemistry and Biophysics. 2026;783:110906. doi:10.1016/j.abb.2026.110906
BibTeX
@article{Zhou2026,
author = {Zhou, Hanxi and Guo, Yiqing and Zhou, Pin and Zheng, Jingmin},
title = {LYPD1 promotes the progression of lung adenocarcinoma through activating the PI3K/AKT signaling pathway},
journal = {Archives of Biochemistry and Biophysics},
year = {2026},
volume = {783},
pages = {110906},
doi = {10.1016/j.abb.2026.110906}
}
EUVIMED